Please assess the completion status of the following clinical trial:

Trial Title: Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Female, 18 years or older~* Histologically confirmed invasive breast cancer~* Bone metastases~* ECOG Performance Status of 0 to 2~* Life expectancy of more than 3 months~* Subject must have adequate organ function:~  * Cr ≤ 3 mg/dL (265 µmol/L)，~ * CrCl (Cockcroft \& Gault) ≥ 30 mL/min，~ * Ca2+ \> 8.0 mg/dL (2.0 mmol/L) and ≤ 12 mg/dL (3.0 mmol/L)~* Negative serum pregnancy test for women with childbearing potential~* Good conditions for infusion and willing to undergo phlebotomy during the whole study~* Have ceased anti-tumor treatment including chemotherapy, endocrinotherapy and bio-targeted therapy for over 28 days~Exclusion Criteria:~* Pregnant or lactating females~* History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety~* Active or uncontrolled infection~* Current active dental problems including infection of the teeth or jawbone (maxilla or mandible); dental or fixture trauma; or a current or prior diagnosis of osteonecrosis of the jaw (ONJ); or exposed bone in the mouth; or slow healing after dental procedures~* Recent (within 6 weeks of Randomization) or planned dental or jaw surgery (e.g. extraction, implants)~* Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure~* Concomitant with liver, brain or symptomatic lung metastases (symptoms such as hemoptysis, severe cough and shortness of breath)~* Accepted radiotherapy for solitary bone disease within 30 days before study~* Previous treatment with other bisphosphonates or radionuclides within one month before study~* Known hypersensitivity to bisphosphonates~* History of treatment with calcitonin, gallium nitrate or mithracin within 14 days before study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- conventional Zometa (Type: ACTIVE_COMPARATOR): Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
- weekly Zometa (Type: EXPERIMENTAL): Weekly Zometa in combination with other antitumor agents one month after the initial dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).